Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Delma Caiati maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $207 to $224.
Guggenheim analyst Delma Caiati maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $207 to $224.